Genomic engineering as a promising cancer therapeutic approach has experienced a tremendous surge since the discovery of the adaptive bacterial immune defense system «CRISPR» and its potential as a gene editing tool over a decade ago.
Nanotechnology researchers have known for years that RNA, the cousin of DNA, is a promisingtool for nanotherapy, in which therapeutic agents can be delivered inside the body via nanoparticles.